Bayer-strengthens-drug-discovery-platform-through-acquisition-of-Vividion-Therapeutics

Acquisition strengthens Bayer’s drug discovery capabilities with cutting-edge chemoproteomics platform / Vividion’s unique approach identifies previously unknown binding pockets in undruggable targets to generate first-in-class novel compounds in indications of high unmet medical need / Vividion’s technology has already proven its applicability pre-clinically in oncology and immune-related diseases, with potential to expand into additional therapeutic areas / Vividion to operate autonomously and on an arm’s length basis / Purchase price of USD 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news